Ostrowski Sisse R, Katzenstein Terese L, Piironen Timo, Gerstoft Jan, Pedersen Bente K, Ullum Henrik
Department of Infectious Diseases, Rigshospitalet, Copenhagen, Denmark.
J Acquir Immune Defic Syndr. 2004 Apr 1;35(4):337-42. doi: 10.1097/00126334-200404010-00002.
High blood levels of the soluble urokinase receptor (suPAR) strongly predict increased mortality in human immunodeficiency virus-1 (HIV-1)-infected patients. This study investigated the plasma concentration of suPAR in 29 treatment-naive HIV-1-infected patients during 5 years treatment with highly active antiretroviral therapy (HAART). Plasma suPAR decreased after introducing HAART, most pronounced during the first treatment year. The change in plasma suPAR was independent of changes in viral replication and CD4+ cells but it was strongly correlated with plasma levels of the soluble TNF receptor II. Compared with healthy individuals, plasma suPAR and sTN-FrII was increased in untreated patients. After initiating HAART, plasma sTNFrII remained increased whereas plasma suPAR decreased to a level comparable with healthy individuals. The present data indicate that the circulating suPAR level is linked to inflammation in untreated as well as HAART-treated HIV-1-infected patients.
可溶性尿激酶受体（suPAR）的高血水平强烈预示着人类免疫缺陷病毒1型（HIV-1）感染患者死亡率的增加。本研究调查了29例未经治疗的HIV-1感染患者在接受高效抗逆转录病毒治疗（HAART）5年期间的血浆suPAR浓度。引入HAART后血浆suPAR下降，在治疗的第一年最为明显。血浆suPAR的变化与病毒复制和CD4+细胞的变化无关，但与可溶性TNF受体II的血浆水平密切相关。与健康个体相比，未经治疗的患者血浆suPAR和sTN-FrII升高。开始HAART后，血浆sTNFrII仍然升高，而血浆suPAR降至与健康个体相当的水平。目前的数据表明，循环suPAR水平与未经治疗以及接受HAART治疗的HIV-1感染患者的炎症有关。
